Advances in meningioma therapy

Current Neurology and Neuroscience Reports

Volumn 9, Issue 3, 2009, Pages 231-240

  Norden, Andrew D ^b   Drappatz, Jan ^b   Wen, Patrick Y ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LONG ACTING DRUG; MIFEPRISTONE; NELFINAVIR; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN RECEPTOR; SOMATOSTATIN; SORAFENIB; SUNITINIB; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; VATALANIB;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME 22Q; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 10; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 19; CHROMOSOME TRANSLOCATION 8; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MENINGIOMA; NEUROPATHOLOGY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STEREOTACTIC RADIOSURGERY; SUSTAINED RELEASE FORMULATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; RADIOSURGERY;

EID: 64649083978     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0034-5     Document Type: Review

References (81)

1. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Available at http://www.cbtrus.org/reports//2007-2008/2007report.pdf. Accessed February 11, 2009.
2. Meningeal tumors. In WHO Classification of Tumors. Tumors of the Nervous System. Edited by Kleihues P, Cavenee WK. Lyon, France: IARC; 2000:175-196.
3. Yang SY, Park CK, Park SH, et al.: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry 2008, 79:574-580.
4. Lamszus K: Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 2004, 63:275-286.
5. Krayenbuhl N, Pravdenkova S, Al-Mefty O: De novo versus transformed atypical and anaplastic meningiomas: Comparisons of clinical course, cytogenetics, cytokinetics, and outcome. Neurosurgery 2007, 61:495-503; discussion 503-494.
6. Pasquier D, Bijmolt S, Veninga T, et al.: Atypical and malignant meningioma: Outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2008, 71:1388-1393.
7. Ruttledge MH, Sarrazin J, Rangaratnam S, et al.: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994, 6:180-184.
8. Simon M, Bostrom JP, HartmannFC: Molecular genetics of meningiomas: from basic research to potential clinical applications. Neurosurgery 2007, 60:787-798; discussion 787-798.
9. Hansson CM, Buckley PG, Grigelioniene G, et al.: Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics 2007, 8:16.
10. Striedinger K, VandenBerg SR, Baia GS, et al.: The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008, 10:1204-1212.
11. Hanemann CO: Magic but treatable? Tumours due to loss of merlin. Brain 2008, 131:606-615.
12. Wozniak K, Piaskowski S, Gresner SM, et al.: BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genet Cytogenet 2008, 183:14-20.
13. Perry A, Cai DX, Scheithauer BW, et al.: Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000, 59:872-879.
14. Gerber MA, Bahr SM, Gutmann DH: Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res 2006, 66:5295-5303.
15. Ketter R, Rahnenfuhrer J, Henn W, et al.: Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Neurosurgery 2008, 62:61-69; discussion 69-70.
16. Ketter R, Urbschat S, Henn W, et al.: Application of oncogenetic trees mixtures as a biostatistical model of the clonal cytogenetic evolution of meningiomas. Int J Cancer 2007, 121:1473-1480.
17. Pfisterer WK, Hendricks WP, Scheck AC, et al.: Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: Is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery 2007, 61:1048-1059; discussion 1060-1041.
18. Maillo A, Orfao A, Espinosa AB, et al.: Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol 2007, 9:438-446.
19. Claus EB, Park PJ, Carroll R, et al.: Specific genes expressed in association with progesterone receptors in meningioma. Cancer Res 2008, 68:314-322.
20. Baia GS, Stifani S, Kimura ET, et al.: Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas. Neoplasia 2008, 10:604-612.
21. Keller A, Ludwig N, Backes C, et al.: Genome wide expression profiling identifies specific deregulated pathways in meningioma. Int J Cancer 2009, 124:346-351.
22. Martinez-Glez V, Franco-Hernandez C, Rey JA: Microarray gene expression profiling in meningiomas and schwannomas. Curr Med Chem 2008, 15:826-833.
23. Aarhus M, Bruland O, Bredholt G, et al.: Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas. J Neurooncol 2008, 88:251-259.
24. Krupp W, Holland H, Koschny R, et al.: Genome-wide genetic characterization of an atypical meningioma by single-nucleotide polymorphism array-based mapping and classical cytogenetics. Cancer Genet Cytogenet 2008, 184:87-93.
25. Bethke L, Murray A, Webb E, et al.: Comprehensive analysis of DNA repair gene variants and risk of meningioma. J Natl Cancer Inst 2008, 100:270-276.
26. Rajaraman P, Wang SS, Rothman N, et al.: Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev 2007, 16:1655-1661.
27. Marosi C, Hassler M, Roessler K, et al.: Meningioma. Crit Rev Oncol Hematol 2008, 67:153-171.
28. Simpson D: The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957, 20:22-39.
29. Black PM, Morokoff AP, Zauberman J: Surgery for extra-axial tumors of the cerebral convexity and midline. Neurosurgery 2008, 62:1115-1121; discussion 1121-1113.
30. Butte PV, Pikul BK, Hever A, et al.: Diagnosis of meningioma by time-resolved fluorescence spectroscopy. J Biomed Opt 2005, 10:064026.
31. Gay E, Vuillez JP, Palombi O, et al.: Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas. Neurosurgery 2005, 57:107-113; discussion 107-113.
32. Morofuji Y, Matsuo T, Hayashi Y, et al.: Usefulness of intraoperative photodynamic diagnosis using 5-aminolevulinic acid for meningiomas with cranial invasion: Technical case report. Neurosurgery 2008, 62:102-103; discussion 103-104.
33. Jaaskelainen J: Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986, 26:461-469.
34. Johnson WD, Loredo LN, Slater JD: Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus 2008, 24:E2.
35. Nakamura M, Roser F, Michel J, et al.: Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas. Zentralbl Neurochir 2005, 66:17-23. al.
36. Zeidman LA, Ankenbrandt WJ, Du H, et al.: Growth rate of non-operated meningiomas. J Neurol 2008, 255:891-895.
37. Goyal LK, Suh JH, Mohan DS, et al.: Local control and overall survival in atypical meningioma: A retrospective study. Int J Radiat Oncol Biol Phys 2000, 46:57-61.
38. Rogers L, Mehta M: Role of radiation therapy in treating intracranial meningiomas. Neurosurg Focus 2007, 23:E4.
39. Milker-Zabel S, Zabel-du Bois A, Huber P, et al.: Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: Long-term experience of a single institution. Int J Radiat Oncol Biol Phys 2007, 68:858-863.
40. Debus J, Wuendrich M, Pirzkall A, et al.: High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: Long-term results. J Clin Oncol 2001, 19:3547-3553.
41. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus 2007, 23:E5.
42. Torres RC, Frighetto L, De Salles AA, et al.: Radiosurgery and stereotactic radiotherapy for intracranial meningiomas. Neurosurg Focus 2003, 14:E5.
43. Chamberlain MC: Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg 1996, 84:733-736.
44. Muhr C, Gudjonsson O, Lilja A, et al.: Meningioma treated with interferon-alpha, evaluated with [(11)C]-l-methionine positron emission tomography. Clin Cancer Res 2001, 7:2269-2276.
45. Chamberlain MC, Tsao-Wei DD, Groshen S: Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004, 62:1210-1212.
46. de Robles P, McIntyre J, Kalra S, et al.: Methylation status of MGMT gene promoter in meningiomas. Cancer Genet Cytogenet 2008, 187:25-27.
47. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 2006, 78:271-276.
48. Newton HB: Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus 2007, 23:E11.
49. Smith JS, Lal A, Harmon-Smith M, et al.: Association between absence of epidermal growth factor receptor immunoreactivity and poor prognosis in patients with atypical meningioma. J Neurosurg 2007, 106:1034-1040.
50. Wen PY, Yung WKA, Lamborn K, et al.: Phase II study of imatinib mesylate (STI571) for patients with recurrent meningiomas (NABTC 01-08) [abstract]. Neuro Oncol 2006, 8:454.
51. Gupta V, Samuleson CG, Su S, Chen TC: Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition. Neurosurg Focus 2007, 23:E9.
52. Lusis EA, Chicoine MR, Perry A: High throughput screening of meningioma biomarkers using a tissue microarray. J Neurooncol 2005, 73:219-223.
53. Crombet T, Torres O, Rodriguez V, et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: Preliminary study. Hybridoma 2001, 20:131-136.
54. Johnson M, Toms S: Mitogenic signal transduction pathways in meningiomas: Novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol 2005, 64:1029-1036.
55. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
56. Lamszus K, Lengler U, Schmidt NO, et al.: Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000, 46: 938-947; discussion 947-938.
57. Kan P, Liu JK, Wendland MM, et al.: Peritumoral edema after stereotactic radiosurgery for intracranial meningiomas and molecular factors that predict its development. J Neurooncol 2007, 83:33-38.
58. ProviasRJ, Claffey K, delAguila L, et al.: Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997, 40:1016-1026.
59. Barresi V, Cerasoli S, Vitarelli E, Tuccari G: Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol 2007, 114:147-156.
60. Kaley T, Wen P, Karimi S, et al.: Phase II trial of sunitinib (SU011248) in patients with recurrent or inoperable meningioma [abstract]. Neuro Oncol 2008, 10:817.
61. Deboer R, Grimm S, Chandler J, et al.: A phase II trial of PTK787/ZK 222584 in recurrent or progressive meningioma [abstract]. Neuro Oncol 2008, 10:824.
62. Klaeboe L, Lonn S, Scheie D, et al.: Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. Int J Cancer 2005, 117:996-1001.
63. Schoenberg BS, Christine BW, Whisnant JP: Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1975, 25:705-712.
64. Blitshteyn S, Crook JE, Jaeckle KA: Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 2008, 26:279-282.
65. Claus EB, Black PM, Bondy ML, et al.: Exogenous hormone use and meningioma risk: What do we tell our patients? Cancer 2007, 110:471-476.
66. Gazzeri R, Galarza M, Gazzeri G: Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 2007, 357:2411-2412.
67. Custer B, Longstreth WT Jr, Phillips LE, et al.: Hormonal exposures and the risk of intracranial meningioma in women: A population-based case-control study. BMC Cancer 2006, 6:152.
68. Wigertz A, Lonn S, Hall P, et al.: Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 2008, 17:2663-2670.
69. Goodwin JW, Crowley J, Eyre HJ, et al.: A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. J Neurooncol 1993, 15:75-77.
70. Grunberg SM, Rankin C, Townsend J, et al.: Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma [abstract]. Proc ASCO 2001, 20:222.
71. McCutcheon IE, Flyvbjerg A, Hill H, et al.: Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001, 94:487-492.
72. Drake WM, Grossman AB, Hutson RK: Effect of treatment with pegvisomant on meningioma growth in vivo. Eur J Endocrinol 2005, 152:161-162.
73. Arena S, Barbieri F, Thellung S, et al.: Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 2004, 66:155-166.
74. Chamberlain MC, Slantz MJ, Fadul CE: Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007, 69:969-973.
75. BrAns C, Lewis I, Briner U, et al.: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146:707-716.
76. Dziuk TW, Woo S,AButler EB, et al.: Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 1998, 37:177-188.
77. Goldsmith BJ, Wara WM, Wilson CB, Larson DA: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994, 80:195-201.
78. Harris AE, Lee JY, Omalu B, et al.: The effect of radiosurgery during management of aggressive meningiomas. Surg Neurol 2003, 60:298-305; discussion 305.
79. Ojemann SG, Sneed PK, Larson DA, et al.: Radiosurgery for malignant meningioma: Results in 22 patients. J Neurosurg 2000, 93(Suppl 3):62-67.
80. Stafford SL, Pollock BE, Foote RL, et al.: Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 2001, 49:1029-1037; discussion 1037-1028.
81. Chamberlain MC, Glantz MJ: Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 2008, 113:2146-2151.